Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
NASDAQ · Healthcare
Amylyx Pharmaceuticals, Inc. Common Stock Shareholder Equity 2021–2025
Amylyx Pharmaceuticals, Inc. Common Stock annual shareholder equity history from 2021 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Amylyx Pharmaceuticals, Inc. Common Stock shareholder equity as of December 31, 2025: 305.3M, a 85.27% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. Common Stock shareholder equity for 2025 were 305.3M, a 85.27% increase from 2024.
- Amylyx Pharmaceuticals, Inc. Common Stock shareholder equity for 2024 were 164.8M, a 61.99% decrease from 2023.
- Amylyx Pharmaceuticals, Inc. Common Stock shareholder equity for 2023 were 433.4M, a 27.25% increase from 2022.
- Amylyx Pharmaceuticals, Inc. Common Stock shareholder equity for 2022 were 340.6M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Amylyx Pharmaceuticals, Inc. Common Stock Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $305 |
| 2024 | $165 |
| 2023 | $433 |
| 2022 | $341 |
| 2021 | $-151 |
Amylyx Pharmaceuticals, Inc. Common Stock Shareholder Equity — FAQ
Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) shareholder equity over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see AMLX's shareholder equity history?
The chart and table above show Amylyx Pharmaceuticals, Inc. Common Stock's shareholder equity by year and by quarter, including the growth rate.